GLS 5700

Drug Profile

GLS 5700

Alternative Names: GLS-5700; Zika dMAb® therapy

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator GeneOne Life Science; Inovio Pharmaceuticals
  • Class DNA vaccines; Monoclonal antibodies; Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Zika virus infection

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 15 Jun 2017 Adverse events data from the phase I ZIKA-001 trial in Zika virus infection released by Inovio
  • 15 Jun 2017 Inovio completes enrolment in the phase I ZIKA-002 trial for Zika virus infection (In adults, In the elderly, In volunteers) in Puerto Rico (Intradermal)
  • 07 Jun 2017 Immunogenicity data from a phase I trial in Zika virus infection (Prevention) released by Inovio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top